Argos Therapeutics (ARGS) Stock Price Up 11.7%

Argos Therapeutics Inc. (NASDAQ:ARGS) rose 11.7% during trading on Friday . The stock traded as high as $1.11 and last traded at $1.05. Approximately 978,771 shares were traded during mid-day trading, an increase of 28% from the average daily volume of 764,584 shares. The stock had previously closed at $0.94.

Separately, ValuEngine raised Argos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

How to Become a New Pot Stock Millionaire

The company has a debt-to-equity ratio of -1.31, a current ratio of 1.80 and a quick ratio of 1.80.

TRADEMARK VIOLATION NOTICE: “Argos Therapeutics (ARGS) Stock Price Up 11.7%” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/13/argos-therapeutics-args-stock-price-up-11-7.html.

About Argos Therapeutics

Argos Therapeutics, Inc, an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply